Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, Glennie MJ, White AL.

Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22.

2.

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.

Turaj AH, Cox KL, Penfold CA, French RR, Mockridge CI, Willoughby JE, Tutt AL, Griffiths J, Johnson PWM, Glennie MJ, Levy R, Cragg MS, Lim SH.

Sci Rep. 2018 Feb 2;8(1):2278. doi: 10.1038/s41598-018-20656-y.

3.

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.

Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, Johnson PWM, Al-Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH.

Cancer Cell. 2017 Dec 11;32(6):777-791.e6. doi: 10.1016/j.ccell.2017.11.001. Epub 2017 Nov 30.

4.

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS, Beers SA.

Cancer Res. 2017 Jul 1;77(13):3619-3631. doi: 10.1158/0008-5472.CAN-16-2784. Epub 2017 May 16.

5.

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.

Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, Leandro MJ.

Rheumatology (Oxford). 2017 Jul 1;56(7):1227-1237. doi: 10.1093/rheumatology/kex067.

6.

Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Cleary KLS, Chan HTC, James S, Glennie MJ, Cragg MS.

J Immunol. 2017 May 15;198(10):3999-4011. doi: 10.4049/jimmunol.1601473. Epub 2017 Apr 12.

7.

Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, Illidge TM, Honeychurch J.

Cancer Immunol Res. 2016 Jul;4(7):621-630. doi: 10.1158/2326-6066.CIR-15-0253. Epub 2016 May 30.

8.

OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.

Lai C, August S, Albibas A, Behar R, Cho SY, Polak ME, Theaker J, MacLeod AS, French RR, Glennie MJ, Al-Shamkhani A, Healy E.

Clin Cancer Res. 2016 Aug 15;22(16):4236-48. doi: 10.1158/1078-0432.CCR-15-2614. Epub 2016 Mar 31.

9.

Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.

Hargreaves CE, Iriyama C, Rose-Zerilli MJ, Nagelkerke SQ, Hussain K, Ganderton R, Lee C, Machado LR, Hollox EJ, Parker H, Latham KV, Kuijpers TW, Potter KN, Coupland SE, Davies A, Stackpole M, Oates M, Pettitt AR, Glennie MJ, Cragg MS, Strefford JC.

PLoS One. 2016 Mar 23;11(3):e0145040. doi: 10.1371/journal.pone.0145040. eCollection 2016. No abstract available.

10.

Influence of immunoglobulin isotype on therapeutic antibody function.

Beers SA, Glennie MJ, White AL.

Blood. 2016 Mar 3;127(9):1097-101. doi: 10.1182/blood-2015-09-625343. Epub 2016 Jan 13. Review.

11.

The INNs and outs of antibody nonproprietary names.

Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RG, Hötzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, Clark MR, Lowe DC, Dahiyat BI, Smith V, Lambert JM, Wu H, Reilly M, Haurum JS, Dübel S, Huston JS, Schirrmann T, Janssen RA, Steegmaier M, Gross JA, Bradbury AR, Burton DR, Dimitrov DS, Chester KA, Glennie MJ, Davies J, Walker A, Martin S, McCafferty J, Baker MP.

MAbs. 2016;8(1):1-9. doi: 10.1080/19420862.2015.1114320.

12.

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.

Hargreaves CE, Iriyama C, Rose-Zerilli MJ, Nagelkerke SQ, Hussain K, Ganderton R, Lee C, Machado LR, Hollox EJ, Parker H, Latham KV, Kuijpers TW, Potter KN, Coupland SE, Davies A, Stackpole M, Oates M, Pettitt AR, Glennie MJ, Cragg MS, Strefford JC.

PLoS One. 2015 Nov 6;10(11):e0142379. doi: 10.1371/journal.pone.0142379. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0145040.

13.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS.

J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28.

14.

CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.

Dong H, Franklin NA, Ritchea SB, Yagita H, Glennie MJ, Bullock TN.

Eur J Immunol. 2015 Dec;45(12):3289-301. doi: 10.1002/eji.201445291. Epub 2015 Nov 6.

15.

Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies.

Fuller JP, Stavenhagen JB, Christensen S, Kartberg F, Glennie MJ, Teeling JL.

Acta Neuropathol. 2015 Nov;130(5):699-711. doi: 10.1007/s00401-015-1484-2. Epub 2015 Oct 3.

16.

Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework.

Offringa R, Glennie MJ.

Cancer Cell. 2015 Sep 14;28(3):273-5. doi: 10.1016/j.ccell.2015.08.008.

17.

Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.

Reddy V, Cambridge G, Isenberg DA, Glennie MJ, Cragg MS, Leandro M.

Arthritis Rheumatol. 2015 May;67(8):2046-55. doi: 10.1002/art.39167.

18.

Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS.

Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005.

19.

Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Vaughan AT, Chan CH, Klein C, Glennie MJ, Beers SA, Cragg MS.

J Biol Chem. 2015 Feb 27;290(9):5424-37. doi: 10.1074/jbc.M114.593806. Epub 2015 Jan 7.

20.

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

Cancer Cell. 2015 Jan 12;27(1):138-48. doi: 10.1016/j.ccell.2014.11.001. Epub 2014 Dec 11.

21.

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.

Hussain K, Hargreaves CE, Roghanian A, Oldham RJ, Chan HT, Mockridge CI, Chowdhury F, Frendéus B, Harper KS, Strefford JC, Cragg MS, Glennie MJ, Williams AP, French RR.

Blood. 2015 Jan 1;125(1):102-10. doi: 10.1182/blood-2014-08-593061. Epub 2014 Nov 13.

22.

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.

White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K, Williams EL, Booth SG, French RR, Potter EA, Butts C, Al-Shamkhani A, Cragg MS, Verbeek JS, Johnson PW, Glennie MJ, Beers SA.

J Immunol. 2014 Aug 15;193(4):1828-35. doi: 10.4049/jimmunol.1303204. Epub 2014 Jul 14.

23.

Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial.

Chowdhury F, Johnson PW, Glennie MJ, Williams AP.

Cancer Immunol Res. 2014 Mar;2(3):229-40. doi: 10.1158/2326-6066.CIR-13-0070. Epub 2013 Nov 21.

24.

Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood.

Chowdhury F, Lode HN, Cragg MS, Glennie MJ, Gray JC.

Cancer Immunol Immunother. 2014 Jun;63(6):559-69.

PMID:
24658837
25.

Fcγ receptor-mediated inflammation inhibits axon regeneration.

Zhang G, Bogdanova N, Gao T, Song JJ, Cragg MS, Glennie MJ, Sheikh KA.

PLoS One. 2014 Feb 11;9(2):e88703. doi: 10.1371/journal.pone.0088703. eCollection 2014.

26.

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity.

Vaughan AT, Iriyama C, Beers SA, Chan CH, Lim SH, Williams EL, Shah V, Roghanian A, Frendéus B, Glennie MJ, Cragg MS.

Blood. 2014 Jan 30;123(5):669-77. doi: 10.1182/blood-2013-04-490821. Epub 2013 Nov 13.

27.

Neutrophils: "neu players" in antibody therapy?

Beers SA, Glennie MJ.

Blood. 2013 Oct 31;122(18):3093-4. doi: 10.1182/blood-2013-09-525451. No abstract available.

28.

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ.

J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.

29.

Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.

He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T.

J Immunol. 2013 Oct 15;191(8):4174-83. doi: 10.4049/jimmunol.1300409. Epub 2013 Sep 11.

30.

Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.

Williams EL, Dunn SN, James S, Johnson PW, Cragg MS, Glennie MJ, Gray JC.

Clin Cancer Res. 2013 Jul 1;19(13):3545-55. doi: 10.1158/1078-0432.CCR-12-3226. Epub 2013 May 6.

31.

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

King BC, Hamblin AD, Savage PM, Douglas LR, Hansen TH, French RR, Johnson PW, Glennie MJ.

Cancer Immunol Immunother. 2013 Jun;62(6):1093-105. doi: 10.1007/s00262-013-1408-8. Epub 2013 Apr 19.

32.

FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.

White AL, Chan HT, French RR, Beers SA, Cragg MS, Johnson PW, Glennie MJ.

Cancer Immunol Immunother. 2013 May;62(5):941-8. doi: 10.1007/s00262-013-1398-6. Epub 2013 Mar 31. Review.

PMID:
23543215
33.

Agonistic CD40 antibodies and cancer therapy.

Vonderheide RH, Glennie MJ.

Clin Cancer Res. 2013 Mar 1;19(5):1035-43. doi: 10.1158/1078-0432.CCR-12-2064.

34.

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).

Williams EL, Tutt AL, French RR, Chan HT, Lau B, Penfold CA, Mockridge CI, Roghanian A, Cox KL, Verbeek JS, Glennie MJ, Cragg MS.

Eur J Immunol. 2012 Aug;42(8):2109-20. doi: 10.1002/eji.201142302. Epub 2012 Jul 4.

35.

Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.

Teeling JL, Carare RO, Glennie MJ, Perry VH.

Acta Neuropathol. 2012 Oct;124(4):479-90. doi: 10.1007/s00401-012-0995-3. Epub 2012 May 18.

36.

Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.

Vitale LA, He LZ, Thomas LJ, Widger J, Weidlick J, Crocker A, O'Neill T, Storey J, Glennie MJ, Grote DM, Ansell SM, Marsh H, Keler T.

Clin Cancer Res. 2012 Jul 15;18(14):3812-21. doi: 10.1158/1078-0432.CCR-11-3308. Epub 2012 May 15.

37.

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.

Otten MA, Bakema JE, Tuk CW, Glennie MJ, Tutt AL, Beelen RH, van de Winkel JG, van Egmond M.

Eur J Immunol. 2012 Jul;42(7):1815-21. doi: 10.1002/eji.201141982.

38.

CD27 stimulation promotes the frequency of IL-7 receptor-expressing memory precursors and prevents IL-12-mediated loss of CD8(+) T cell memory in the absence of CD4(+) T cell help.

Dong H, Franklin NA, Roberts DJ, Yagita H, Glennie MJ, Bullock TN.

J Immunol. 2012 Apr 15;188(8):3829-38. doi: 10.4049/jimmunol.1103329. Epub 2012 Mar 14.

39.

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg MS, Glennie MJ.

Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18.

40.

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ.

J Immunol. 2011 Aug 15;187(4):1754-63. doi: 10.4049/jimmunol.1101135. Epub 2011 Jul 8.

41.

Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy.

Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RH, Valerius T, Lohse S, Glennie MJ, Medema JP, van Egmond M.

J Immunol. 2011 Jul 15;187(2):726-32. doi: 10.4049/jimmunol.1002581. Epub 2011 Jun 8.

42.

Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration.

Lunnon K, Teeling JL, Tutt AL, Cragg MS, Glennie MJ, Perry VH.

J Immunol. 2011 Jun 15;186(12):7215-24. doi: 10.4049/jimmunol.0903833. Epub 2011 May 13.

43.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM.

Blood. 2011 Apr 28;117(17):4519-29. doi: 10.1182/blood-2010-07-296913. Epub 2011 Mar 4.

44.

Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.

Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, Bullock TN.

J Immunother. 2010 Oct;33(8):769-79. doi: 10.1097/CJI.0b013e3181ee238f.

45.

Guidelines for the welfare and use of animals in cancer research.

Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA; Committee of the National Cancer Research Institute.

Br J Cancer. 2010 May 25;102(11):1555-77. doi: 10.1038/sj.bjc.6605642.

46.

Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant.

White AL, Tutt AL, James S, Wilkinson KA, Castro FV, Dixon SV, Hitchcock J, Khan M, Al-Shamkhani A, Cunningham AF, Glennie MJ.

Immunology. 2010 Sep;131(1):141-51. doi: 10.1111/j.1365-2567.2010.03285.x. Epub 2010 May 10.

47.

CD20 as a target for therapeutic type I and II monoclonal antibodies.

Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ.

Semin Hematol. 2010 Apr;47(2):107-14. doi: 10.1053/j.seminhematol.2010.01.001. Review.

PMID:
20350657
48.

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg MS.

Blood. 2010 Jun 24;115(25):5191-201. doi: 10.1182/blood-2010-01-263533. Epub 2010 Mar 11.

49.

Complement: help or hindrance?

Beers SA, Cragg MS, Glennie MJ.

Blood. 2009 Dec 24;114(27):5567-8; author reply 5568. doi: 10.1182/blood-2009-10-249466. No abstract available.

50.

Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 perforin expressing T cells enriched for human cytomegalovirus specificity and an effector-memory phenotype.

Walton JA, Lydyard PM, Nathwani A, Emery V, Akbar A, Glennie MJ, Porakishvili N.

Br J Haematol. 2010 Jan;148(2):274-84. doi: 10.1111/j.1365-2141.2009.07964.x. Epub 2009 Nov 4.

PMID:
19895614

Supplemental Content

Loading ...
Support Center